US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Invesco Dorsey Wright Healthcare Momentum ETF

60.21

+0.54820.92%

Post-market: 60.20-0.0082-0.01%19:30 EDT

Volume:14.83K

Turnover:889.95K

Market Cap:291.41M

PE:19.69

High:60.29

Open:60.11

Low:59.81

Close:59.66

52wk High:64.10

52wk Low:44.47

Shares:4.84M

Float Shares:4.84M

Volume Ratio:0.30

T/O Rate:0.31%

Dividend:1.53

Dividend Rate:2.53%

EPS(TTM):3.06

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Huihe Medical's STAR Market IPO Application Terminated; Company Focuses on Innovative Medical Devices in Panvascular Intervention

Lifetech Scientific's SureCham Aortic Arch Single-Branch Stent Graft System Enters Special Review Pathway for Innovative Medical Devices

Bioperfectus Secures Two Medical Device Registration Certificates

Maccura Biotechnology Secures Three Medical Device Registration Certificates

Revolution Medicines (RVMD) Gets a Buy from Goldman Sachs

Wainwright maintains confidence in Immunovant’s pipeline despite CLE setback

Sector Update: Healthcare

MT Newswires Live

Update: US Equity Futures Slightly Lower Pre-Bell as Traders Await Developments in US-Iran Talks

MT Newswires Live

Roivant Sciences price target raised to $41 from $37.50 at BofA

Immunovant Falls After Lupus Drug Setback

Roivant Says IMVT-1402 Cutaneous Lupus Study Misses Primary Endpoint, Halts Development in CLE

Roivant Sciences - Imvt-1402 Demonstrates Favorable Safety and Tolerability Profile

THOMSON REUTERS

Roivant Announces Topline Results from Proof-of-Concept Study of Imvt-1402 in Cutaneous Lupus Erythematosus

THOMSON REUTERS

Roivant Sciences - All Other Clinical Development Timelines Remain on Track

THOMSON REUTERS

Axsome Therapeutics, Inc. : Truist Securities Assumes Coverage with Buy Rating; Target Price $285 vs $200

THOMSON REUTERS

Revolution Medicines Chief Global Commercialization Officer Anthony Mancini Disposes of Common Shares Worth $347,000

Lucid Diagnostics advances Medicare reimbursement and coding infrastructure

AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib

Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015

Shinva Medical Subsidiary Secures Class III Medical Device Approvals

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/PTH/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PTH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTH\",,,,,undefined,":{"symbol":"PTH","market":"US","secType":"STK","nameCN":"Invesco Dorsey Wright Healthcare Momentum ETF","latestPrice":60.2082,"timestamp":1790971200000,"preClose":59.66,"halted":0,"volume":14828,"hourTrading":{"tag":"盘后","latestPrice":60.2,"preClose":60.2082,"latestTime":"19:30 EDT","volume":10,"amount":602.441,"timestamp":1790983804674,"change":-0.0082,"changeRate":-0.000136,"amplitude":0},"delay":0,"changeRate":0.009188736171639313,"floatShares":4840000,"shares":4840000,"eps":3.057033,"marketStatus":"Market Closed","change":0.5482,"latestTime":"10-02 16:00:00 EDT","open":60.11,"high":60.29,"low":59.81,"amount":889950.01788,"amplitude":0.008046,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":3.057033,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":59.66,"sharesOutstanding":2480000,"nav":59.60729,"aum":291451253.04,"dividendRate":0.02533,"bidAskSpread":0.001966,"postHourTrading":{"tag":"盘后","latestPrice":60.2,"preClose":60.2082,"latestTime":"19:30 EDT","volume":10,"amount":602.441,"timestamp":1790983804674,"change":-0.0082,"changeRate":-0.000136,"amplitude":0},"volumeRatio":0.3015856226959714,"impliedVol":0.1149,"impliedVolPercentile":0.4024},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTH\",,,,,undefined,":{"symbol":"PTH","floatShares":4840000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.3015856226959714,"shares":4840000,"dividePrice":1.5251,"high":60.29,"amplitude":0.008046,"preClose":59.66,"low":59.81,"week52Low":44.47,"pbRate":"--","week52High":64.1,"institutionHeld":0,"latestPrice":60.2082,"eps":3.057033,"divideRate":0.02533,"volume":14828,"delay":0,"ttmEps":3.057033,"open":60.11,"prevYearClose":49.701,"prevWeekClose":61.596,"prevMonthClose":60.76,"prevQuarterClose":60.76,"fiveDayClose":61.596,"twentyDayClose":61.3641,"sixtyDayClose":61.67},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PTH\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PTH","amount":1.52645,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Dorsey Wright Healthcare Momentum ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2024-06-24","symbol":"PTH","amount":0.02545,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-24","defaultRemindTime":1719235800000,"name":"Invesco Dorsey Wright Healthcare Momentum ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-28","payableDate":"2024-06-24","currency":"USD","dateTimestamp":1719201600000,"payDate":"2024-06-28"},{"market":"US","date":"2023-07-17","symbol":"PTH","defaultRemindTime":1689600600000,"type":"split","dateTimestamp":1689566400000,"forFactor":1,"toFactor":3,"ratio":0.3333333333333333}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PTH\",market:\"US\",,,undefined,":[{"executeDate":"2024-06-24","recordDate":"2024-06-24","paymentDate":"2024-06-28","value":0.02545,"currency":"USD"},{"executeDate":"2025-12-22","recordDate":"2025-12-22","paymentDate":"2025-12-26","value":1.52645,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PTH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PTH\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1193610255","title":"Huihe Medical's STAR Market IPO Application Terminated; Company Focuses on Innovative Medical Devices in Panvascular Intervention","url":"https://stock-news.laohu8.com/highlight/detail?id=1193610255","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193610255?lang=en_us&edition=fundamental","pubTime":"2026-09-24 20:54","pubTimestamp":1790254489,"startTime":"0","endTime":"0","summary":"Huihe Medical's STAR Market IPO review status was changed to \"terminated\" on September 24, as the company and its sponsor withdrew the listing application, according to the relevant provisions of the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4127","GDOC","09996","REDS","IPOS","BK1100","BK1574","KSTR","LGHT","LNGR","AGNG","HART","BK1583","KCE","FRHC","PTH","159883","IEIH","MEDX","RSPH","MDEV","159891"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104658454","title":"Lifetech Scientific's SureCham Aortic Arch Single-Branch Stent Graft System Enters Special Review Pathway for Innovative Medical Devices","url":"https://stock-news.laohu8.com/highlight/detail?id=1104658454","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104658454?lang=en_us&edition=fundamental","pubTime":"2026-09-24 20:16","pubTimestamp":1790252179,"startTime":"0","endTime":"0","summary":"Lifetech Scientific (01302) has announced that on September 24, 2026, the company received formal written notification from the National Medical Products Administration confirming that the SureCham...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159883","LNGR","BK1574","01302","GDOC","MEDX","RSPH","09996","HART","AGNG","IEIH","PTH","LGHT","BK1600","MDEV","BK1583","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131609096","title":"Bioperfectus Secures Two Medical Device Registration Certificates","url":"https://stock-news.laohu8.com/highlight/detail?id=1131609096","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131609096?lang=en_us&edition=fundamental","pubTime":"2026-09-24 17:20","pubTimestamp":1790241617,"startTime":"0","endTime":"0","summary":"Bioperfectus Technologies (688399.SH) announced that it has recently received medical device registration certificates (in vitro diagnostic reagents) issued by the National Medical Products...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159883","IEIH","688399","BK1100","LNGR","PTH","LGHT","09996","HART","MDEV","BK1583","BK0239","AGNG","GDOC","MEDX","RSPH","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198667592","title":"Maccura Biotechnology Secures Three Medical Device Registration Certificates","url":"https://stock-news.laohu8.com/highlight/detail?id=1198667592","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198667592?lang=en_us&edition=fundamental","pubTime":"2026-09-24 16:59","pubTimestamp":1790240378,"startTime":"0","endTime":"0","summary":"Maccura Biotechnology Co.,Ltd. (300463.SZ) has announced that the company recently received three Medical Device Registration Certificates issued by the Sichuan Provincial Medical Products...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNGR","HART","BK1100","PTH","BK1574","159883","BK0046","09996","MDEV","BK0028","BK0012","GDOC","LGHT","BK1583","300463","AGNG","RSPH","BK0239","MEDX","IEIH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669918463","title":"Revolution Medicines (RVMD) Gets a Buy from Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2669918463","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669918463?lang=en_us&edition=fundamental","pubTime":"2026-09-24 16:35","pubTimestamp":1790238933,"startTime":"0","endTime":"0","summary":"Goldman Sachs analyst Andrea Newkirk resumed coverage with a Buy rating on Revolution Medicines today and set a price target of $267.00. Newkirk co...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/revolution-medicines-rvmd-gets-a-buy-from-goldman-sachs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/revolution-medicines-rvmd-gets-a-buy-from-goldman-sachs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1668664300.SGD","BK4127","LU2237443622.USD","LU1868836757.USD","IE00BSNM7G36.USD","LU2896262040.SGD","LU0942090050.USD","IE00BJJMRZ35.SGD","LU1804176565.USD","LU1144417596.USD","LU0096364046.USD","LU0868494708.USD","LU2237443382.USD","BK4588","BBH","IE00BFXG1179.USD","CANC","LU0345770993.USD","LU0210536198.USD","LU0251142724.SGD","IE0009354923.USD","LU0109394709.USD","IE00B2B36J28.USD","IE0002270589.USD","IE0034235188.USD","IE00BJT1NW94.SGD","LU0742534661.SGD","PTH","GSX","LU1894683264.USD","LU2750360997.AUD","LU1791807156.HKD","LU0061475181.USD","BK4552","IE00BFTCPJ56.SGD","IE0004086264.USD","LU2471134523.USD","LU0345770308.USD","LU2237438978.USD","LU1868836591.USD","BK4550","LU1894683348.USD","LU0251131958.USD","BK4533","LU2237443895.HKD","LU0106831901.USD","IE00B19Z3B42.SGD","LU2237443978.SGD","RVMD","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669438437","title":"Wainwright maintains confidence in Immunovant’s pipeline despite CLE setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2669438437","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669438437?lang=en_us&edition=fundamental","pubTime":"2026-09-24 01:20","pubTimestamp":1790184011,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Douglas Tsao notes that this morning, Roivant Sciences (ROIV) reported that IMVT-1402 missed the Week 12 Cutaneous Lupus Er...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/wainwright-maintains-confidence-in-immunovants-pipeline-despite-cle-setback-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/wainwright-maintains-confidence-in-immunovants-pipeline-despite-cle-setback-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ROIV","BK4139","BK4007","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669486413","title":"Sector Update: Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2669486413","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669486413?lang=en_us&edition=fundamental","pubTime":"2026-09-23 21:00","pubTimestamp":1790168425,"startTime":"0","endTime":"0","summary":"Healthcare stocks were steady premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF  slightly declining and the iShares Biotechnology ETF  inactive.Roivant Sciences  said its Immunovant  subsidiary plans to stop development of IMVT-1402 in cutaneous lupus erythematosus after a proof-of-concept study failed to achieve statistical significance on the primary endpoint. Shares of Immunovant and Roivant were down 6.1% and 1%, respectively, pre-bell.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","PTH","XBI","XLV","BK4585","HCSG","BK4588","IBB","BK4581","LABU","ROIV","IMVT","LU0029874061.USD","BK4137","BK4007","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669372486","title":"Update: US Equity Futures Slightly Lower Pre-Bell as Traders Await Developments in US-Iran Talks","url":"https://stock-news.laohu8.com/highlight/detail?id=2669372486","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669372486?lang=en_us&edition=fundamental","pubTime":"2026-09-23 20:48","pubTimestamp":1790167737,"startTime":"0","endTime":"0","summary":"(Updates with economic data, recent oil price movements, world markets' overview, and corporate stock movements.)US equity futures were slightly lower pre-bell Wednesday as traders awaited development","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1670628061.USD","BK4517","BK4139","BK4585","CARX","IONL","BK4168","BK4113","BK4588","IONZ","LU1366192091.USD","IOYY","RCL","WQTM","BK4142","COAL","BK4602","LU0266013472.USD","BK4141","CART","IMVT","IONQ","BK4591","BHP","QTUP","BK4566","WNDR","ROIV","SLX","BK4170","LU0300736062.USD","LU1670627923.USD","BK4007","PTH","IONX","LU0300736492.USD","IONC","CQTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669048537","title":"Roivant Sciences price target raised to $41 from $37.50 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2669048537","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669048537?lang=en_us&edition=fundamental","pubTime":"2026-09-23 20:15","pubTimestamp":1790165711,"startTime":"0","endTime":"0","summary":"BofA analyst Chi Fong raised the firm’s price target on Roivant Sciences (ROIV) to $41 from $37.50 and keeps a Neutral rating on the shares after h...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roivant-sciences-price-target-raised-to-41-from-37-50-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roivant-sciences-price-target-raised-to-41-from-37-50-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ROIV","PTH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669483473","title":"Immunovant Falls After Lupus Drug Setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2669483473","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669483473?lang=en_us&edition=fundamental","pubTime":"2026-09-23 20:04","pubTimestamp":1790165052,"startTime":"0","endTime":"0","summary":"BUZZ-Immunovant falls after lupus drug setback** Shares of biotech firm ImmunovantIMVT.Ofall 4.5% to $35.6 premarket** Stock set to open at its lowest level in over three months, if losses hold** Co p","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nL6N45F0L8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","ROIV","PTH","BK4585","BK4007","IMVT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669269100","title":"Roivant Says IMVT-1402 Cutaneous Lupus Study Misses Primary Endpoint, Halts Development in CLE","url":"https://stock-news.laohu8.com/highlight/detail?id=2669269100","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669269100?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:05","pubTimestamp":1790161507,"startTime":"0","endTime":"0","summary":"Roivant says IMVT-1402 cutaneous lupus study misses primary endpoint, halts development in CLERoivant reported topline results from a proof-of-concept study of IMVT-1402 in cutaneous lupus erythematos","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nNDL5xYLBJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","BK4112","BK4139","LU2210149790.SGD","SG9999014013.SGD","IE00BGHQF748.EUR","BK4588","SG9999014005.SGD","IE00BQXX3D17.EUR","LU2095319765.USD","IE00B64PRP62.GBP","BK4585","IE00BN0W2V16.EUR","LU2210150020.SGD","NDAQ","IE00B3QW5Z07.USD","SG9999014039.USD","BCDF","PTH","LU0314104364.USD","ROIV","BK4007","IE00BQXX3C00.GBP","IE00BKPKM429.USD","SG9999014021.USD","IE00BQXX3F31.USD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669676100","title":"Roivant Sciences - Imvt-1402 Demonstrates Favorable Safety and Tolerability Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2669676100","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669676100?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:00","pubTimestamp":1790161201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nTUA6JH70M:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTH","BK4007","BK4139","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669100988","title":"Roivant Announces Topline Results from Proof-of-Concept Study of Imvt-1402 in Cutaneous Lupus Erythematosus","url":"https://stock-news.laohu8.com/highlight/detail?id=2669100988","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669100988?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:00","pubTimestamp":1790161201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nTUA6JH70M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4139","ROIV","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669006461","title":"Roivant Sciences - All Other Clinical Development Timelines Remain on Track","url":"https://stock-news.laohu8.com/highlight/detail?id=2669006461","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669006461?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:00","pubTimestamp":1790161201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nTUA6JH70M:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ROIV","BK4139","BK4007","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669310159","title":"Axsome Therapeutics, Inc. : Truist Securities Assumes Coverage with Buy Rating; Target Price $285 vs $200","url":"https://stock-news.laohu8.com/highlight/detail?id=2669310159","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669310159?lang=en_us&edition=fundamental","pubTime":"2026-09-23 17:03","pubTimestamp":1790154221,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nFWN45F0EI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2324357040.USD","BK4585","BK4007","AXSM","PTH","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669120310","title":"Revolution Medicines Chief Global Commercialization Officer Anthony Mancini Disposes of Common Shares Worth $347,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2669120310","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669120310?lang=en_us&edition=fundamental","pubTime":"2026-09-23 06:00","pubTimestamp":1790114446,"startTime":"0","endTime":"0","summary":"Revolution Medicines Chief Global Commercialization Officer Anthony Mancini disposes of common shares worth $347,000Revolution Medicines Chief Global Commercialization Officer Anthony Mancini sold 1,7","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDL64Mcy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Revolution Medicines Chief Global Commercialization Officer Anthony Mancini Disposes of Common Shares Worth $347,000","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","LU0889565916.HKD","RVMD","IDNA","IE0009355771.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0320765992.SGD","IE00BJT1NW94.SGD","LU0109394709.USD","PTH","BK4139","CANC","IE0009354923.USD","IE0002141913.USD","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669147769","title":"Lucid Diagnostics advances Medicare reimbursement and coding infrastructure","url":"https://stock-news.laohu8.com/highlight/detail?id=2669147769","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669147769?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:29","pubTimestamp":1790083753,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics ( ($LUCD) ) has provided an update. On September 22, 2026, Lucid Diagnostics announced key advances in payment, billing and codin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lucid-diagnostics-advances-medicare-reimbursement-and-coding-infrastructure?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lucid-diagnostics-advances-medicare-reimbursement-and-coding-infrastructure?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMED","TMED","FXH","BK4099","IHF","IE00B775SV38.USD","LU1267930490.SGD","LU0868494617.USD","LU1084165304.USD","MHIP","REZ","SG9999014013.SGD","BK4588","LCIZ","BK4551","IHI","BK4585","LU0708994859.HKD","XLVI","LCDL","XLVX","MEDI","LUCD","IE00B3S45H60.SGD","AGNG","HTEC","LCID","LU0310800379.SGD","IEHS","IYH","HCA","SG9999014039.USD","TRUH","CURE","FHLC","MHIG","PTH","BK4082","RSPH","JHMH","RXD","PSCH","XHE","LNGR","LU1150488135.SGD","PINK","DVXV","LU0310799852.SGD","LU0433182093.SGD","LU0203347892.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142210","title":"AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142210","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142210?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:55","pubTimestamp":1790081700,"startTime":"0","endTime":"0","summary":"Daraxonrasib is an important therapeutic advance, but pancreatic cancer is not a simple disease where one successful targeted drug makes additional therapeutic development unnecessary. We believe Ampligen has the potential to complement and extend therapies such as daraxonrasib by helping to overcome the immune biological barriers that have h","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/22/3366375/29489/en/aim-immunotech-highlights-ampligen-s-potential-role-in-the-evolving-pancreatic-cancer-treatment-landscape-following-fda-approval-of-revolution-medicines-daraxonrasib.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CANC","IE0009355771.USD","LU0889565916.HKD","PTH","RVMD","IE00B2B36J28.USD","LU0109394709.USD","BBH","BK4139","IE0002141913.USD","LABU","IDNA","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","IE0009354923.USD","IE00BJT1NW94.SGD","BK4588","IE00B4R5TH58.HKD","LU0320765992.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669144047","title":"Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015","url":"https://stock-news.laohu8.com/highlight/detail?id=2669144047","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669144047?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:30","pubTimestamp":1790080200,"startTime":"0","endTime":"0","summary":"New Preclinical PDAC Package for PRP Shows >90% Tumor-Growth Inhibition & >2.5-Fold Survival Benefit; Company Contrasts Mechanism, Breadth, & Development Role Against Erasca’s Phase 1 ERAS-0015 Datase","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/22/3366329/0/en/propanc-biopharma-highlights-differentiated-prp-pancreatic-cancer-data-versus-emerging-pan-ras-program-eras-0015.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BYTNYN87.SGD","LU0359202008.SGD","IE00B12V2V27.USD","BK4605","LU0109394709.USD","LU1720051017.SGD","PDX","LU2357305700.SGD","TME","ERAS","IE00BYQNZ168.SGD","PPCB","ONX","BK4509","LU1548497426.USD","IDNA","LU2298322129.HKD","LU0269904917.USD","BK4571","BK4585","BK4588","LU2360107325.USD","SG9999011746.SGD","BK4565","IE0002141913.USD","IE0009354923.USD","BK4108","IE00BJT1NW94.SGD","LU1861219969.SGD","LU0509642566.USD","LU1854103824.USD","LU1854104046.USD","ON","BK4531","LU1023057109.AUD","RVMD","LU0724618433.USD","ONG","LU1861220033.SGD","BK4141","BK4535","IE00BFTCPJ56.SGD","LU0320765992.SGD","CANC","01698","BK4139","PTH","BK4512","BK4548","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107418547","title":"Shinva Medical Subsidiary Secures Class III Medical Device Approvals","url":"https://stock-news.laohu8.com/highlight/detail?id=1107418547","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107418547?lang=en_us&edition=fundamental","pubTime":"2026-09-22 15:40","pubTimestamp":1790062838,"startTime":"0","endTime":"0","summary":"Shinva Medical Instrument Co., Ltd. (600587.SH) has announced that its subsidiary, Shinva Surgical Instruments Co., Ltd., recently received the Medical Device Registration Certificates issued by...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","IEIH","HART","159883","BK0251","BK1100","MEDX","LNGR","09996","BK1574","BK0028","MDEV","LGHT","BK1583","GDOC","RSPH","600587","AGNG","BK0188"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}